Chronic kidney disease

Chinook Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
Tuesday, November 22, 2022

Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.

Key Points: 
  • Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases.
  • Chinooks product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.
  • Chinooks lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and proteinuric glomerular diseases.
  • In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases.

Vera Therapeutics to Host Key Opinion Webinar on Targeting the Source of IgA Nephropathy (IgAN) Featuring Jonathan Barratt, Ph.D., FRCP

Retrieved on: 
Thursday, November 17, 2022

BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that it will host a key opinion leader (KOL) webinar on IgA nephropathy (IgAN), a common cause of kidney failure. The webinar will be held on Monday, November 28, 2022 at 2:00pm ET.

Key Points: 
  • Recent data presented by Dr. Barratt at the American Society of Nephrology (ASN) Kidney Week 2022 showed atacicept reduced immune complex levels in patients with IgAN.
  • In addition, the Vera Therapeutics leadership team will provide an overview of the ongoing Phase 2b ORIGIN trial of atacicept in IgAN and the Companys pipeline.
  • If the data from the ORIGIN trial are supportive, Vera Therapeutics expects to initiate a pivotal Phase 3 clinical trial of atacicept in 2023.
  • Atacicept showed a dose-dependent effect on key biomarkers and clinical markers in a Phase 2a clinical study in patients with IgAN.

XORTX Therapeutics Appoints Stacy Evans, M.D., MBA as Chief Business Officer

Retrieved on: 
Wednesday, November 16, 2022

CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer.

Key Points: 
  • CALGARY, Alberta, Nov. 16, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the appointment of Stacy Evans, M.D., MBA, as Chief Business Officer.
  • For the past seven years, Dr. Evans has consulted at an executive level with small to mid-size private and public biopharmaceutical companies, including acting as Chief Business Officer for many clients.
  • Allen Davidoff, Ph.D., Chief Executive Officer of XORTX, stated, We are pleased to welcome Stacy to the team as Chief Business Officer.
  • Dr. Evans brings extensive large and small pharma licensing and M&A experience to XORTX and will lead our increasingly active commercial assessment and business development activities.

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Retrieved on: 
Wednesday, November 16, 2022

The company plans to open enrollment shortly and dose the first subject of the study in December 2022.

Key Points: 
  • The company plans to open enrollment shortly and dose the first subject of the study in December 2022.
  • We are very excited to be initiating our DMT clinical stroke research program with our Phase 1 study at CHDR in the Netherlands, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

Retrieved on: 
Tuesday, November 15, 2022

Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease.

Key Points: 
  • Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease.
  • Due to low public awareness, people living with rare kidney disease can face challenges in getting diagnosed and finding support.
  • Rare kidney disease often presents with unique symptoms or no symptoms and can progress to end-stage kidney disease much faster than other forms of kidney disease, said Kelly Helm, executive director of patient engagement at NephCure Kidney International.
  • Anyone with an authentic connection to rare kidney disease is encouraged to submit a letter on RKDandMe.com to support raising awareness of RKD.

Sigyn Therapeutics Announces Third Quarter 2022 Financial Results

Retrieved on: 
Tuesday, November 15, 2022

SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solutions to address unmet needs in global health, today announces financial results for the third quarter ended September 30, 2022 and provides an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire Sigyn Therapeutics, Inc. (Sigyn or the Company) (OTCQB: SIGY), a development-stage company focused on creating therapeutic solutions to address unmet needs in global health, today announces financial results for the third quarter ended September 30, 2022 and provides an update on recent corporate developments.
  • Announced plans to pursue first-in-human feasibility studies of Sigyn Therapy in End-Stage Renal Disease patients suffering from excess inflammation and/or endotoxemia.
  • For complete financial results, please see Sigyn Therapeutics filings at www.sec.gov , and on the Company's website at www.SigynTherapeutics.com under "Financial Info" in the Investors section.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Unicycive Announces Third Quarter Financial Results and Provides Business Update

Retrieved on: 
Monday, November 14, 2022

LOS ALTOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) --  Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the third quarter ended September 30, 2022, and provided a business update.

Key Points: 
  • The third quarter of 2022 and recent weeks have been particularly productive as we completed enrollment of our pivotal bioequivalence trial of RENAZORB, with topline results expected by year-end.
  • We remain on track to file a New Drug Application (NDA) in 2023, saidShalabh Gupta, M.D., Chief Executive Officer of Unicycive.
  • Dr. Gupta added, We were delighted to share favorable results from both our product candidates with the nephrology community at this years Kidney Week.
  • General and administrative expenses for the quarter ended September 30, 2022 were $1.7 million, compared with $0.9 million for the same quarter in 2021.

ProKidney Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Retrieved on: 
Monday, November 14, 2022

WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney or the Company), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney or the Company), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.
  • During the third quarter of 2022, we made significant advancement in our mission to improve the lives and outcomes for people with CKD.
  • In July, ProKidney listed on the Nasdaq exchange and raised capital that optimally positions us to meet our anticipated clinical milestones.
  • Our Phase 2 clinical trial, REGEN-007, remains on track to report interim data by the third quarter of 2023.

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

Retrieved on: 
Friday, November 18, 2022

This new biomarker data is in addition to the previously-announced significant reduction in new collagen deposition (57%) observed in a preclinical fibrosis model and provides the potential for new intellectual property.

Key Points: 
  • This new biomarker data is in addition to the previously-announced significant reduction in new collagen deposition (57%) observed in a preclinical fibrosis model and provides the potential for new intellectual property.
  • Revelation plans to initiate a Phase 1b clinical study in patients undergoing elective cardiac surgery in the second half of 2023.
  • Revelation originally announced on October 25, 2022 positive results from the preclinical model of acute kidney injury and chronic kidney disease.
  • Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease.

Ursa Health Launches Healthcare Data Analytics Solution to Support Organizations Participating in the ACO REACH Alternative Payment Model

Retrieved on: 
Friday, November 18, 2022

Ursa Studio spans the full breadth of healthcare data work in one no-code platform, including raw data ingestion and integration , data modeling , analytics development , and business intelligence .

Key Points: 
  • Ursa Studio spans the full breadth of healthcare data work in one no-code platform, including raw data ingestion and integration , data modeling , analytics development , and business intelligence .
  • Key capabilities for ACO REACH participants include Ursa Health Data Integration Modules designed specifically to accelerate the process of mapping new data sources into fully enriched, analytics-ready data model tables.
  • The Ursa Health Data Integration Module for CCLF/ACO REACH essentially automates the wrangling of these various files to unlock any and all downstream analytics.
  • The GPDC Model will transition to the ACO REACH Model January 1, 2023, with the model performance period running through 2026.